肿瘤细胞治疗研究
英文原题：Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.
儿童、青少年和年轻成人（CAYA）复发和/或难治性（R/R）非霍奇金淋巴瘤（NHL）的预后极差（2 年总生存期低于 25%）。
儿童、青少年和年轻成人（CAYA）复发和/或难治性（R/R）非霍奇金淋巴瘤（NHL）的预后极差，2年总生存率低于25%。亟需为这一高危人群开发新型靶向疗法。CD19、CD20、CD22、CD79a、CD38、CD30、LMP1和LMP2是CAYA患者R/R NHL免疫治疗的有吸引力靶点。目前正在R/R阶段研究新型抗CD20单克隆抗体、抗CD38单克隆抗体、抗体药物偶联物，以及靶向T细胞和自然杀伤（NK）细胞的双特异性和三特异性衔接器，这些疗法正在改变NHL治疗格局。研究者还考察了多种细胞免疫疗法，包括病毒激活细胞毒性T淋巴细胞、嵌合抗原受体（CAR）T细胞、NK细胞和CAR-NK细胞，为CAYA患者R/R NHL提供了替代选择。本文更新这类细胞免疫疗法和体液免疫疗法的进展，并提供其用于CAYA患者R/R NHL的临床实践指导。
The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. CD19, CD20, CD22, CD79a, CD38, CD30, LMP1 and LMP2 are attractive targets for immunotherapy in CAYA patients with R/R NHL. Novel anti-CD20 monoclonal antibodies, anti-CD38 monoclonal antibody, antibody drug conjugates and T and natural killer (NK)-cell bispecific and trispecific engagers are being investigated in the R/R setting and are changing the landscape of NHL therapy. A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
